Difference between revisions of "Epoetin alfa (Procrit)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Jwarner moved page Epoetin alfa (Procrit) to Erythropoietin)
m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information")
 
(15 intermediate revisions by 4 users not shown)
Line 1: Line 1:
 
==General information==
 
==General information==
−
Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors.<ref name="insert">[http://www.procrit.com/shared/product/procrit/procrit-prescribing-information.pdf Epoetin alfa (Procrit) package insert]</ref><ref>[[Media:Epoetin.pdf | Epoetin alfa (Procrit) package insert (locally hosted backup)]]</ref><ref>[http://www.procrit.com Procrit manufacturer's website]</ref>
+
Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors.<ref name="insert">[http://www.procrit.com/shared/product/procrit/procrit-prescribing-information.pdf Epoetin alfa (Procrit) package insert]</ref><ref>[[:File:Epoetin.pdf | Epoetin alfa (Procrit) package insert (locally hosted backup)]]</ref><ref>[http://www.procrit.com Procrit manufacturer's website]</ref><ref>As of 4/14/2017, use of this medication in patients with oncologic diagnoses no longer requires enrollment in the ESA APPRISE Risk Evaluation and Mitigation Strategy (REMS) Program</ref>
 
<br>Route: SC, IV
 
<br>Route: SC, IV
 
<br>Extravasation: no information
 
<br>Extravasation: no information
−
*[http://www.esa-apprise.com/ ESA APPRISE Risk Evaluation and Mitigation Strategy (REMS) Program]<ref>[http://www.esa-apprise.com/ ESA APPRISE Risk Evaluation and Mitigation Strategy (REMS) Program]</ref>
 
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref>
 +
 
 +
==Diseases for which it is used==
 +
*[[Myelodysplastic syndrome]]
  
 
==Patient drug information==
 
==Patient drug information==
−
*[http://www.procrit.com/shared/product/procrit/procrit-instructions-for-use.pdf Epoetin alfa (Procrit) patient instructions for use]<ref>[http://www.procrit.com/shared/product/procrit/procrit-instructions-for-use.pdf Epoetin alfa (Procrit) patient instructions for use]</ref><ref>[[Media:Epoetin instructions.pdf | Epoetin alfa (Procrit) patient instructions for use (locally hosted backup)]]</ref>
+
*[http://www.procrit.com/shared/product/procrit/procrit-instructions-for-use.pdf Epoetin alfa (Procrit) patient instructions for use]<ref>[http://www.procrit.com/shared/product/procrit/procrit-instructions-for-use.pdf Epoetin alfa (Procrit) patient instructions for use]</ref><ref>[[:File:Epoetin instructions.pdf | Epoetin alfa (Procrit) patient instructions for use (locally hosted backup)]]</ref>
 
*Brief patient counseling information can be found in [http://www.procrit.com/shared/product/procrit/procrit-prescribing-information.pdf the Epoetin alfa (Procrit) package insert]<ref name="insert"></ref>
 
*Brief patient counseling information can be found in [http://www.procrit.com/shared/product/procrit/procrit-prescribing-information.pdf the Epoetin alfa (Procrit) package insert]<ref name="insert"></ref>
−
*[http://chemocare.com/chemotherapy/drug-info/epoetin-alfa.aspx Epoetin alfa (Procrit) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/epoetin-alfa.aspx Epoetin alfa (Procrit) patient drug information (Chemocare)]</ref>
+
*[https://chemocare.com/druginfo/epoetin-alfa.aspx Epoetin alfa (Procrit) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/epoetin-alfa.aspx Epoetin alfa (Procrit) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/epoetin-alfa-patient-drug-information Epoetin alfa (Procrit) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/epoetin-alfa-patient-drug-information Epoetin alfa (Procrit) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/epoetin-alfa-patient-drug-information Epoetin alfa (Procrit) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/epoetin-alfa-patient-drug-information Epoetin alfa (Procrit) patient drug information (UpToDate)]</ref>
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
−
* 6/1/1989: Initial FDA approval
+
* 1989-06-01: Initial FDA approval
  
 
==Also known as==
 
==Also known as==
−
{| border="1" style="text-align:center;"
+
*'''Generic names:''' Erythropoetin, Erythropoietin
−
!colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms'''
+
*'''Brand names:''' Ceriton, Dynepo, Epoch, Epofer, Epogen, Epogin, Epoimmun, Epomax, Epopen, Epox, Epoyet, Eprex, Eritrelan, Erypo, Erythrostim, Espo, Globuren, Hemapo, Hemax, LG Espogen, Procrit, Recormon, Vepox, Vintor, Wepox
−
|-
 
−
|Ceriton
 
−
|Dynepo
 
−
|Epoch
 
−
|Epoetin
 
−
|Epoetin Alfa
 
−
|Epoetin Beta
 
−
|Epoetin Delta
 
−
|Epoetin Zeta
 
−
|-
 
−
|Epofer
 
−
|Epogen
 
−
|Epogin
 
−
|Epoimmun
 
−
|Epomax
 
−
|Epopen
 
−
|Epox
 
−
|Epoyet
 
−
|-
 
−
|Eprex
 
−
|Eritrelan
 
−
|Erypo
 
−
|Erypo FS
 
−
|Erythropoetin
 
−
|Erythropoietin
 
−
|Erythropoietin Human
 
−
|Erythrostim
 
−
|-
 
−
|Espo
 
−
|Espo Kirin
 
−
|Espo Sankyo
 
−
|Globuren
 
−
|Hemapo
 
−
|Hemax
 
−
|KE Long YI BAO
 
−
|LG Espogen
 
−
|-
 
−
|Procrit
 
−
|Recormon
 
−
|Recormon N
 
−
|Recormon NEU
 
−
|Recormon PS
 
−
|Recormon S
 
−
|Recormon SE
 
−
|Vepox
 
−
|-
 
−
|Vintor
 
−
|Wepox
 
−
|}
 
  
 
==References==
 
==References==
 
<references/>
 
<references/>
  
−
[[Category:Drug index]]
+
[[Category:Drugs]]
 +
[[Category:Intravenous medications]]
 +
[[Category:Subcutaneous medications]]
 
[[Category:Hematopoietic growth factors]]
 
[[Category:Hematopoietic growth factors]]
 
[[Category:Erythrocyte growth factors]]
 
[[Category:Erythrocyte growth factors]]
  
−
[[Category:REMS program]]
+
[[Category:Myelodysplastic syndrome medications]]
−
[[Category:Drugs FDA approved in 1989]]
+
 
 +
[[Category:FDA approved in 1989]]

Latest revision as of 01:06, 29 June 2024

General information

Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors.[1][2][3][4]
Route: SC, IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 1989-06-01: Initial FDA approval

Also known as

  • Generic names: Erythropoetin, Erythropoietin
  • Brand names: Ceriton, Dynepo, Epoch, Epofer, Epogen, Epogin, Epoimmun, Epomax, Epopen, Epox, Epoyet, Eprex, Eritrelan, Erypo, Erythrostim, Espo, Globuren, Hemapo, Hemax, LG Espogen, Procrit, Recormon, Vepox, Vintor, Wepox

References

  1. ↑ 1.0 1.1 1.2 Epoetin alfa (Procrit) package insert
  2. ↑ Epoetin alfa (Procrit) package insert (locally hosted backup)
  3. ↑ Procrit manufacturer's website
  4. ↑ As of 4/14/2017, use of this medication in patients with oncologic diagnoses no longer requires enrollment in the ESA APPRISE Risk Evaluation and Mitigation Strategy (REMS) Program
  5. ↑ Epoetin alfa (Procrit) patient instructions for use
  6. ↑ Epoetin alfa (Procrit) patient instructions for use (locally hosted backup)
  7. ↑ Epoetin alfa (Procrit) patient drug information (Chemocare)
  8. ↑ Epoetin alfa (Procrit) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Epoetin_alfa_(Procrit)&oldid=87394"